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Despite the rapid advances in fetal medicine and pediatric surgery, congenital chylothoraces have an
associated mortality of 22e65% and an increased morbidity resulting from pulmonary hypoplasia, severe
infections secondary to immune globulin deﬁciencies, protein malnutrition, and coagulopathy. While the
mainstay of therapy is medical management, large volume chylothoraces often require surgical man-
agement. In both the prenatal and postnatal periods, the recommended management of congenital
chylothoraces is still controversial. We present a case of a prenatally diagnosed large chylothorax
associated with a cervical lymphatic malformation. In our patient, the chylothorax persisted despite
optimal postnatal medical management with drainage by tube thoracostomy, TPN, and octreotide.
Adjuvant therapies included sirolimus and sclerotherapy directed toward the treatment of the macro-
cystic lymphatic malformation. We report the ﬁrst case of a persistent congenital chylothorax associated
with a lymphatic malformation successfully treated with thoracoscopic talc pleurodesis and
sclerotherapy.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Congenital chylothoraces are uncommon conditions, with an
estimated occurrence of 1:10,000 to 1:15,000 pregnancies and an
associated mortality of 22e65% [1,2]. Secondary causes of a
congenital chylothorax include maternal or fetal infection, hydrops
fetalis, fetomaternal hemorrhage, fetal anemia, congenital heart
disease, congenital pulmonary lesions (congenital cystic adeno-
matoid malformations, bronchopulmonary sequestration),
congenital diaphragmatic hernia, and lymphatic malformations [3].
In the postnatal patient, ongoing loss of lymphatic ﬂuid via drainage
of a high output chylothorax has been associated with risk of severe
infection (observed in 33% of patients with congenital chylothorax),egenerative Biology, Depart-
icine, University of Colorado
lex 2, Room 6400, 12700 E.
86; fax: þ1 303 724 6330.
. Hodges).
Inc. This is an open access article uhypoproteinemia, hypogammaglobulinemia, and coagulopathy. An
interdisciplinary medical and surgical approach is recommended
due to the complexity of the disease and potential adverse sequelae
[4,5].We present the ﬁrst reported case of amassive (>50 cc/kg/day
output) congenital chylothorax associated with a lymphatic mal-
formation of the neck that failed to respond to maximum medical
management and was ultimately treated successfully with talc
pleurodesis.1. Case
A 30 year-old woman presented at 33 weeks gestation for
routine follow up and was noted to have a fundal height greater
than expected. Subsequent fetal US identiﬁed the presence of pol-
yhydramnios, as well as bilateral moderate to large pleural effu-
sions. Further antenatal evaluation with magnetic resonance
imaging (MRI), demonstrated polyhydramnios, a large right pleuralnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. AP ﬂuoroscopy view of the baby’s neck following injection of intralesional
contrast and doxycycline into the right cervical macrocystic lymphatic malformation
(black arrow).
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volume ascites (Fig. 1). A complex, multiseptated, cervical cystic
structure (3.2 cm  1.1 cm  2.3 cm) was also noted and appeared
consistent with a macrocystic lymphatic malformation. Additional
evaluation for sources of secondary pleural effusion demonstrated a
normal fetal male karyotype, negative maternal screening for
congenital infectious diseases (CMV, parvovirus, and toxoplas-
mosis), a negative maternal serum antibody test, and a fetal echo-
cardiogram demonstrating normal cardiac structure and function.
Given the polyhydramnios and mediastinal shift resulting from
the fetal hydrothorax, amnioreduction and ultrasound-guided right
fetal thoracentesis was performed for both diagnostic and thera-
peutic purposes. Pleural ﬂuid analysis demonstrated a cell count of
5187 cells/mL with 96% lymphocytes, consistent with the diagnosis
of a chylothorax. Ultrasound performed the next day demonstrated
rapid reaccumulation of moderate size bilateral chylothoraces.
Given the rapid reaccumulation of bilateral chylothoraces, the de-
cision was made to induce labor at 36 3/7 weeks gestational age
(GA) in order to mitigate the risk of late term prenatal demise. US-
guided right fetal thoracentesis was repeated, and vaginal delivery
was subsequently induced. The baby boy was born at 36 3/
7 weeks GA, weighing 2780 g.
Upon delivery, Apgar scores were 1, 4, and 7 at 1, 5, and 10 min,
respectively. The baby was immediately noted to be apneic and to
have poor tone; his breathing was assisted with bag mask venti-
lation followed by endotracheal intubation and initiation of
inotropic support for concomitant hypotension. He was transferred
to the neonatal intensive care unit (NICU), where a right-sided tube
thoracostomy was performed, with drainage of 156 cc of serous
ﬂuid and radiographically conﬁrmed resolution of his pleural
effusion. The baby was initially managed conservatively, including
being kept nil per os (NPO), using total parenteral nutrition (TPN),
and replacing chest tube output 1:1 every 4 hours, with equal parts
fresh frozen plasma (FFP) and 5% albumin. Over his ﬁrst three days
of life, the patient’s chest tube output remained high (72e96 cc/kg/
day), and an intravenous octreotide infusion was begun on day of
life (DOL) #4, beginning at a rate of 1 mcg/kg/h, and advancing to a
peak rate of 6 mcg/kg/h by DOL#8. In addition, on DOL#4 the pa-
tient underwent sclerotherapy to treat the macrocystic cervical
lymphatic malformation (Fig. 2), and was started on sirolimus to
assist with resolution of the lesion.
Despite continuation of medical therapy, by DOL#8, the patient’s
chest tube output remained elevated at 75 cc/kg/day, without
response to initiation of either octreotide or sirolimus. WithFig. 1. (A) Coronal T2-weighted MRI image demonstrating a large right pleural effusion (wh
macrocystic lymphatic malformation (black arrow). (B) Comparison US long view of the
hemidiaphragm.concern for newly diagnosed lymphopenia, as well as ongoing
losses of protein, immunoglobulins, and coagulation factors, the
decision was made to proceed with operative intervention, despite
having not achieved the recommended octreotide rate of 10 mcg/
kg/h [6]. On DOL#8, the patient underwent right-sided thoraco-
scopic talc pleurodesis. Intraoperative explorationwas unsuccessful
in identifying a discrete intrathoracic lesion responsible for the
patient’s continued chyle leak; therefore, pleurodesis was per-
formed with aerosolized talc. The patient tolerated the procedure
well; postoperatively, his chest tube output immediately and pre-
cipitously decreased to 2 cc/kg/day and remained negligible until
his chest tube was discontinued. The sirolimus was continued until
DOL#12, when it was discontinued due to supratherapeutic serum
levels and concern for contributing immunosuppression in the
setting of acquired bacteremia. Following treatment of the patient’s
bacteremia with intravenous antibiotics, the sirolimus was notite arrow) with mediastinal shift and a cystic lesion in the right neck consistent with a
fetal chest shows a large pleural effusion (white arrow) with ﬂattening of the right
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negligible chest tube output.
On DOL#14/POD#7, the patient was started on enteral feeds
with Enfaport (medium chain triglyceride formula), and TPN was
discontinued three days later when the patient was tolerating full
enteral feeds without a change in chest tube output. The patient
was extubated on POD#8 to CPAP and gradually weaned to room
air. The right chest tube was discontinued on DOL#29/POD#22.
Patient was discharged home on DOL#35, tolerating full enteral
feeds with Enfaport and 10% breast milk. At the time of manuscript
submission, patient was 9 months old, meeting developmental
milestones, on a diet of full breast milk, and was without evidence
of redevelopment of his chylothorax on chest radiograph, despite
cessation of sirolimus therapy on DOL#12 (Fig. 3).2. Discussion
Management of congenital chylothoraces includes treatment of
an underlying etiology, ligation of the thoracic duct, chemical
pleurodesis, intrapleural maternal blood patch, mechanical pleu-
rodesis, pleuroperitoneal shunt, and pleurectomy [1,4,7,8]. Medical
management focuses upon maneuvers which minimize chyle pro-
duction, such as keeping the patient NPO, nutritional support with
TPN, enteral feeds with medium chain triglycerides, and intrave-
nous octreotide [9]. However, in patients whose tube thoracostomy
output remains high despite maximal medical therapy, consider-
ation of early operative intervention, including talc pleurodesis,
may minimize complications and reduce overall length of stay [4].
While previous studies recommend consideration of operative
intervention if chylous drainage remains >15 cc/kg/day after 7 days
of maximal medical management, recent studies have recom-
mended that output >50 cc/kg/day (deﬁned as a ‘massive’ chylo-
thorax) despite maximal medical therapy for 3 days should be an
indication to proceed with early surgical intervention [7,10]. A
recent study in 34 adults with non-traumatic chylothoraces
demonstrated that thoracic duct embolization was successful in
over 60% of patients with an abnormal lymphangiogram; however,
lymphatic channel embolization can be technically challenging in
the neonatal population [11]. More commonly, mechanical pleu-
rodesis, pleurectomy, or chemical pleurodesis have been the
mainstays of treatment for congenital chylothoraces. Given concern
for the risk of blood loss associated with pleurectomy in neonatal
patients, chemical pleurodesis should be considered when imagingFig. 3. AP radiograph of the chest at the time of discharge demonstrates almost
complete resolution of bilateral pleural effusions with only trace residual effusion on
the right (white arrow).fails to demonstrate an etiology amenable to thoracic duct ligation
or embolization. Congenital chylothoraces that remain unrespon-
sive to mechanical or chemical pleurodesis are treated with either
pleuroperitoneal shunts or pleurectomy; however, there is concern
as to whether the neonatal peritoneal cavity is able to accommo-
date and absorb the volumes of chyle that can be produced by
massive congenital chylothoraces [4].
In the pediatric population, there is ongoing debate regarding
the optimal agent for chemical pleurodesis. While a meta-analysis
in adults demonstrated over 90% success rate with the use of
povidone-iodine to treat pleural effusions, it’s use in the pediatric
population has been limited due to concerns regarding an increased
risk of renal failure, acidosis, acute respiratory distress syndrome,
and associated mortality with its use in pediatric patients [4,12,13].
Several recent case reports document successful treatment of fetal
pleural effusions with in-utero pleurodesis using OK-432, a lyoph-
ilized version of low virulence Group A Streptococcus, speciﬁcally
when pleuroamniotic shunting has failed; however, OK-432 is no
longer available in the United States [14e17]. Alternatively, chem-
ical pleurodesis with talc is considered the most effective therapy
for adults with malignant pleural effusions or spontaneous pneu-
mothoraces [18]. After case reports questioned an increased risk of
acute respiratory distress syndrome (ARDS) following talc pleu-
rodesis, a multicenter, randomized trial failed to demonstrate an
association between talc pleurodesis and ARDS in adults [18];
furthermore, two prospective, randomized studies examining the
effectiveness of pleurodesis with talc versus povidone-iodine
demonstrated equal efﬁcacy, without signiﬁcant difference in
adverse events (recurrence, ARDS, or hypotension) [12,19].Wewere
unable to ﬁnd a single case report, let alone a prospective trial,
examining the impact of talc pleurodesis on the natural history of
congenital chylothoraces.
Our patient underwent serial antenatal thoracentesis, followed
by postnatal tube thoracostomy and sclerotherapy directed at
treatment of his underlying macrocystic lymphatic malformation.
Postnatally, our patient was initially managed medically, receiving
the full beneﬁt of a multidisciplinary team of neonatalogists, pe-
diatric surgeons, hematologist-oncologists, and interventional ra-
diologists; however, after 3 days of maximal medical management,
as well as sclerotherapy and the initiation of sirolimus targeted at
treatment of his cervical cystic lymphatic malformation, his chest
tube output remained very high (75 cc/kg/day) [20]. Sirolimus, also
known as rapamycin, is an inhibitor of the mammalian target of
rapamycin (mTOR). In a number of vascular anomalies, speciﬁcally
those demonstrating atypical lymphatic pathology, mTOR expres-
sion is upregulated [21]. Case reports have documented the effec-
tive treatment of chylothoraces associated with lymphatic
malformation using sirolimus [21e23]. As the average time to
response in these cases was 25 days, given time, it is possible that
our patient’s chylothorax would have resolved with medical man-
agement, given time. However, our patient’s ongoing chest tube
output remained very high (75 cc/kg/day) and, faced with rapid
clinical decompensation, an alternative therapeutic approach was
required. In accordance with the recommendations of Cleveland
et al. (2009), we felt the patient would beneﬁt from early surgical
intervention in order to minimize the risks of ongoing chylous
losses, including his known lymphopenia, and the risk of severe
infection, coagulopathy, electrolyte abnormalities, and hypo-
proteinemia. Given the large literature base in adult populations,
the lack of reported adverse events with talc versus povidone-
iodine, and the lack of access to OK-432 in the United States, we
chose to utilize talc pleurodesis in the treatment of our patient; we
observed near immediate resolution of the patient’s congenital
chylothorax, without evidence of recurrence or adverse event four
months postoperatively.
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In the setting of a high volume congenital chylothorax, ante-
natal intervention with either serial thoracentesis or pleuro-
amniotic shunting should be pursued to minimize the associated
morbidity and mortality due to pulmonary hypoplasia. Chemical
pleurodesis has been demonstrated to be safe and effective for
neonatal patients with chylothoraces unresponsive to medical
management; however, the speciﬁc agent of choice remains
undeﬁned. We have presented a case of a patient with a cervical
lymphatic malformation and massive congenital chylothorax,
which was unresponsive to medical management and was treated
very successfully with thoracoscopic talc pleurodesis. In the
setting of a large volume congenital chylothorax resistant to
medical management, talc pleurodesis should be considered early
given the risk of hypoproteinemia, hypogammaglobulinemia,
leukopenia, coagulopathy, volume shifts and electrolyte distur-
bances, and potentially fatal infections risked by ongoing losses of
lymphatic ﬂuid.
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